

**CLAIMS**

1. Use of an extract of a brown alga of the genus *Halopteris*  
5 in a cosmetic or pharmaceutical composition intended to limit  
the expansion of adipose tissues by its effect on pre-adipocyte  
differentiation.
2. Use according to Claim 1, characterised in that the said  
10 alga is the alga *Halopteris scoparia*.
3. Use according to Claim 1 or 2, characterised in that the  
said extract is obtained by the maceration of dried or freeze-  
dried alga in the presence of a solvent, such as water, or a  
15 mixture of water with a co-solvent.
4. Use according to Claim 3, characterised in that the said  
co-solvent is dipropylene glycol or glycerol.
- 20 5. Use according to Claim 4, characterised in that the ratio  
between water and co-solvent is between 0 and 80%.
6. Use according to Claim 5, characterised in that the ratio  
between water and co-solvent is between 30 and 50%.
- 25 7. Cosmetic or pharmaceutical composition intended to limit  
the expansion of adipose tissues, characterised in that it  
comprises, as an active product, at least one extract of the  
brown alga of the genus *Halopteris* which acts so as to inhibit  
30 adipocyte differentiation.
8. Cosmetic or pharmaceutical composition according to Claim  
7, characterised in that the said alga is the alga *Halopteris*

*scoparia.*

9. Cosmetic or pharmaceutical composition according to Claim 7 or 8, characterised in that the said extract is obtained by the maceration of dried or freeze-dried alga in the presence of a solvent, such as water, or a mixture of water with a co-solvent.

10. Cosmetic or pharmaceutical composition according to Claim 9, characterised in that the said co-solvent is dipropylene glycol or glycerol.

11. Cosmetic or pharmaceutical composition according to Claim 9 or 10, characterised in that the ratio between water and co-solvent is between 0 and 80%.

12. Cosmetic or pharmaceutical composition according to Claim 9 or 10, characterised in that the ratio between water and co-solvent is between 30 and 50%.

13. Cosmetic or pharmaceutical composition according to one of Claims 7 to 12, characterised in that it also comprises an active agent stimulating lipolysis and/or an active agent inhibiting lipogenesis.

14. Use of a cosmetic composition according to one of the preceding Claims 7 to 13 for the purpose of limiting the expansion of adipose tissues by inhibiting pre-adipocyte differentiation.

## SINGLE PLATE

5 Fig. 1

% Inhibition of differentiation.

10	Extract of	Extract of	Extract of	Retinoic
	Halopteris 0.5%	Halopteris 1.0%	Halopteris 2.5%	acid 10 $\mu$ M

15

Fig. 2

Presence from D0 to D7	Presence from D0 to D2	Presence from D2 to D7
------------------------	------------------------	------------------------

20 % Inhibition of differentiation

Extract of Halopteris 1%	Retinoic acid 10 $\mu$ M
--------------------------	--------------------------